Skip to content
  • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • For Patients
  • Publications
  • Investors
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
  • Careers
  • Contact
  • About Us
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • For Patients
  • Publications
  • Investors
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
  • Careers
  • Contact

SAFUSIDENIB

The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Publications, SAFUSIDENIB / natalia

The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas Read More »

A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model

Publications, SAFUSIDENIB / natalia

A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model Read More »

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma

Publications, SAFUSIDENIB / natalia

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma Read More »

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates.

About us

  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Pipeline
  • News
  • Careers
  • Contact
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Pipeline
  • News
  • Careers
  • Contact

General Inquiries

info@nuvationbio.com

Media or Investor Inquiries

IR@nuvationbio.com

Linkedin

© 2024 NUVATION BIO INC. ALL RIGHTS RESERVED. TERMS AND CONDITIONS | PRIVACY POLICY

NUVATION BIO, INC.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
NUVATION BIO, INC.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}